Our study sought to help address this question by reviewing multi-institutional data for patients with small, node-negative, HER2+ breast cancer to compare clinical outcomes between those who go untreated versus those who receive adjuvant trastuzumab therapy, with or without chemotherapy. This evidence concerns the gene ERBB2 and breast cancer.